BRPI0212341B8 - compostos intermediários de inibidores de protease de hiv e processo para preparação dos mesmos - Google Patents

compostos intermediários de inibidores de protease de hiv e processo para preparação dos mesmos

Info

Publication number
BRPI0212341B8
BRPI0212341B8 BRPI0212341A BR0212341A BRPI0212341B8 BR PI0212341 B8 BRPI0212341 B8 BR PI0212341B8 BR PI0212341 A BRPI0212341 A BR PI0212341A BR 0212341 A BR0212341 A BR 0212341A BR PI0212341 B8 BRPI0212341 B8 BR PI0212341B8
Authority
BR
Brazil
Prior art keywords
preparing
intermediate compounds
hiv protease
same
protease inhibitors
Prior art date
Application number
BRPI0212341A
Other languages
English (en)
Other versions
BR0212341A (pt
BRPI0212341B1 (pt
Inventor
Rudolf Romanie Kesteleyn Bart
Louis Nestor Ghislain Surleraux Dominique
Jan Leonard Mario Quaedflieg Peter
Original Assignee
Janssen R&D Ireland
Janssen Sciences Ireland Uc
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8180908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0212341(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen R&D Ireland, Janssen Sciences Ireland Uc, Tibotec Pharm Ltd filed Critical Janssen R&D Ireland
Publication of BR0212341A publication Critical patent/BR0212341A/pt
Publication of BRPI0212341B1 publication Critical patent/BRPI0212341B1/pt
Publication of BRPI0212341B8 publication Critical patent/BRPI0212341B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)

Abstract

inibidor de protease de hiv, compostos intermediários e processo para preparação dos mesmos. a presente invenção refere-se a um método para preparação de hexaidro-furo[2,3-b]furan-3-ol, bem como novos intermediários para uso no método. mais especificamente, a invenção refere-se a um método estereosseletivo para a preparação de hexaidro-furo[2,3-b]furan-3-ol e a um método receptível em escala industrial.
BRPI0212341A 2001-09-10 2002-09-06 compostos intermediários de inibidores de protease de hiv e processo para preparação dos mesmos BRPI0212341B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01203416 2001-09-10
EP01203416.1 2001-09-10
PCT/EP2002/010062 WO2003022853A1 (en) 2001-09-10 2002-09-06 Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol

Publications (3)

Publication Number Publication Date
BR0212341A BR0212341A (pt) 2004-07-27
BRPI0212341B1 BRPI0212341B1 (pt) 2019-04-02
BRPI0212341B8 true BRPI0212341B8 (pt) 2021-05-25

Family

ID=8180908

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0212341A BRPI0212341B8 (pt) 2001-09-10 2002-09-06 compostos intermediários de inibidores de protease de hiv e processo para preparação dos mesmos

Country Status (27)

Country Link
US (1) US7126015B2 (pt)
EP (1) EP1448567B1 (pt)
JP (1) JP4521185B2 (pt)
KR (1) KR100894673B1 (pt)
CN (2) CN100519561C (pt)
AP (1) AP1758A (pt)
AR (1) AR036501A1 (pt)
AT (1) ATE453648T1 (pt)
AU (1) AU2002333809C1 (pt)
BR (1) BRPI0212341B8 (pt)
CA (1) CA2459168C (pt)
CY (1) CY1109974T1 (pt)
DE (1) DE60234952D1 (pt)
DK (1) DK1448567T3 (pt)
EA (1) EA010883B1 (pt)
ES (1) ES2338538T3 (pt)
HR (1) HRP20040320B1 (pt)
HU (1) HU229505B1 (pt)
IL (2) IL160166A0 (pt)
MX (1) MXPA04002247A (pt)
NO (1) NO328934B1 (pt)
NZ (1) NZ531641A (pt)
PL (1) PL224030B1 (pt)
PT (1) PT1448567E (pt)
SI (1) SI21463B (pt)
WO (1) WO2003022853A1 (pt)
ZA (1) ZA200401501B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004002975A1 (en) * 2002-06-27 2004-01-08 Smithkline Beecham Corporation PREPARATION OF STEREOISOMERS OF (3ALPHA, 3ALPHA/BETA, 6ALPHA/BETA) HEXAHYDROFURO[2,3-b]FURAN-3-OL
WO2004060895A1 (ja) * 2002-12-27 2004-07-22 Sumitomo Chemical Company, Limited ヘキサヒドロフロフラノール誘導体の製造方法、その中間体及びその製造方法
ME01059B (me) 2003-12-23 2012-10-20 Janssen Sciences Ireland Uc Proces za pripremanje (3r,3as,6ar)-heksahidrofuro [2,3-b] furan-3-il (1s,2r)-3-[[(4-aminofenil) sulfonil] (izobutil) amino]-1-benzil-2- hidroksipropilkarbamata
TWI383975B (zh) * 2004-03-31 2013-02-01 悌柏泰克醫藥有限公司 製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
JP5549898B2 (ja) * 2006-03-31 2014-07-16 独立行政法人産業技術総合研究所 ５−ヒドロキシメチル−２−フルフラールの製造法
MX2009004957A (es) * 2006-11-09 2009-05-19 Tibotec Pharm Ltd Metodos para la preparacion de hexahidrofuro[2,3-b]furan-3-ol.
CN101024646B (zh) * 2007-02-06 2010-07-14 启东东岳药业有限公司 4-甲氧基呋喃并呋喃-2-酮的纯化方法
US8076513B2 (en) 2007-04-27 2011-12-13 Tibotec Pharmaceuticals Ltd. Methods for the preparation of N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl)-p-nitrobenzenesulfonylamide derivatives
US8592487B2 (en) 2007-10-26 2013-11-26 Concert Pharmaceuticals, Inc. Deuterated darunavir
AR073248A1 (es) 2008-09-01 2010-10-20 Tibotec Pharm Ltd Proceso para la preparacion de (1s, 2r)-3- ((4-aminofenil) sulfonil) ( isobutil) amino)-1- bencil-2- hidroxipropilcarbamato de (3r, 3as,6ar)- hexahidrofuro-(2,3-b) furan-3- ilo (darunavir) y compuestos intermediarios utiles en dicho proceso.
US20110257111A1 (en) * 2008-10-24 2011-10-20 Harbeson Scott L Hydroxyethlamino Sulfonamide Derivatives
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
WO2011051978A2 (en) 2009-10-30 2011-05-05 Lupin Limited A novel process for preparation of darunavir and darunavir ethanolate of fine particle size
PL2528923T3 (pl) 2010-01-28 2015-01-30 Mapi Pharma Ltd Sposób wytwarzania darunawiru i pochodnych darunawiru
DK2643326T3 (en) 2010-11-23 2017-01-09 Mylan Laboratories Ltd A process for the preparation of (3R, 3aS, 6aR) -hexahydrofuro [2,3-b] furan-3-ol
US8802724B2 (en) 2010-11-30 2014-08-12 Purdue Research Foundation Processes and intermediates for preparing substituted hexahydrofuro [2,3-b] furans
WO2014016660A2 (en) 2012-07-24 2014-01-30 Laurus Labs Private Limited A process for preparation of darunavir
CN104520262A (zh) * 2012-08-09 2015-04-15 住友化学株式会社 六氢呋喃并呋喃醇衍生物的制造方法
CN103864813B (zh) * 2012-12-18 2017-02-22 上海迪赛诺化学制药有限公司 一种合成六氢呋喃并[2,3‑b]呋喃‑3‑醇及其对映体的方法
US10633390B2 (en) * 2015-06-25 2020-04-28 Msn Laboratories Private Limited Process for the preparation of [(1S,2R)-3-[[(4-aminophenyl)sulfonyl] (2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-carbamic acid (3R,3AS,6AR)hexahydro furo [2,3-B]furan-3-YL ester and its amorphous form
WO2017041228A1 (zh) * 2015-09-08 2017-03-16 浙江九洲药业股份有限公司 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法
CN107043385B (zh) * 2016-02-05 2019-07-09 成都博腾药业有限公司 一种制备地瑞那韦中间体的方法
EP3532478B1 (en) 2016-10-27 2021-05-26 Gilead Sciences, Inc. Crystalline form of darunavir free base
CN106928248B (zh) * 2017-02-04 2019-01-04 青岛科技大学 一种制备(3R,3aS,6aR)六氢呋喃并[2,3-b]呋喃-3-醇的方法
CN110272398B (zh) 2018-03-16 2022-11-29 江苏瑞科医药科技有限公司 六氢呋喃并呋喃醇衍生物的制备方法、其中间体及其制备方法
US20240043438A1 (en) * 2020-08-11 2024-02-08 Arun K. Ghosh Methods for making darunavir p2-ligand precursors
CN114853774A (zh) * 2022-06-24 2022-08-05 盐城迪赛诺制药有限公司 一种达卢那韦关键中间体的制备方法
CN115557964A (zh) * 2022-10-18 2023-01-03 启东东岳药业有限公司 一种药物化合物的制备方法
CN117186053A (zh) * 2023-09-08 2023-12-08 上海凌凯医药科技有限公司 一种莱克酮中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4325970A (en) * 1980-10-09 1982-04-20 Hoffmann-La Roche Inc. 15-Acetyl-prostaglandins
NZ224497A (en) * 1987-05-18 1990-04-26 Janssen Pharmaceutica Nv Pharmaceutical composition comprising flunarizine
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
AU6828894A (en) * 1993-05-14 1994-12-12 Merck & Co., Inc. Hiv protease inhibitors
EP0715618B1 (en) 1993-08-24 1998-12-16 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
RU2089545C1 (ru) * 1994-09-28 1997-09-10 Ярославский государственный технический университет Способ получения 2-метил-2-этил-1,3-диоксолан-4-ил-метилметакрилата
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel
EP1331002A3 (en) * 1997-01-30 2004-01-14 Novartis AG Oil-free pharmaceutical compositions containing cyclosporin A
PT2336134T (pt) * 1998-06-23 2016-10-19 The Board Of Trustees Of The Univ Of Illionis Ensaio de aptidão e métodos para reduzir a resistência do hiv à terapia
WO1999067254A2 (en) * 1998-06-23 1999-12-29 The United States Of America Represented By The Secretary, Department Of Health And Human Services Multi-drug resistant retroviral protease inhibitors and use thereof
KR100336090B1 (ko) * 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
DE19906310A1 (de) * 1999-02-16 2000-08-17 Solvay Pharm Gmbh Arzneimittel zur Behandlung von Bluthochdruck
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
EP1222192B8 (en) * 1999-10-06 2008-10-01 Tibotec Pharmaceuticals Ltd. Hexahydrofuro¬2,3-b furan-3-yl-n- 3-¬(1,3-benzodioxol-5-ylsulfonyl)(isobutyl)amino -1-benzyl-2-hydroxypropyl carbamate as retroviral protease inhibitor

Also Published As

Publication number Publication date
BR0212341A (pt) 2004-07-27
PL224030B1 (pl) 2016-11-30
US20040249175A1 (en) 2004-12-09
AR036501A1 (es) 2004-09-15
PT1448567E (pt) 2010-03-12
HU229505B1 (hu) 2014-01-28
HUP0402140A3 (en) 2007-05-29
IL160166A (en) 2012-05-31
CA2459168A1 (en) 2003-03-20
ES2338538T3 (es) 2010-05-10
AP2004002981A0 (en) 2004-03-31
CN100519561C (zh) 2009-07-29
HK1068887A1 (en) 2005-05-06
ATE453648T1 (de) 2010-01-15
JP2005502707A (ja) 2005-01-27
CN1553915A (zh) 2004-12-08
KR100894673B1 (ko) 2009-04-24
AU2002333809B8 (en) 2008-07-03
AU2002333809B2 (en) 2008-02-28
KR20040029425A (ko) 2004-04-06
CN101172980B (zh) 2011-11-16
HUP0402140A2 (hu) 2005-02-28
EA200400430A1 (ru) 2004-08-26
EP1448567B1 (en) 2009-12-30
HRP20040320B1 (hr) 2012-11-30
ZA200401501B (en) 2005-07-27
CA2459168C (en) 2014-01-28
IL160166A0 (en) 2004-07-25
WO2003022853A1 (en) 2003-03-20
BRPI0212341B1 (pt) 2019-04-02
PL367817A1 (en) 2005-03-07
SI21463B (sl) 2011-08-31
EA010883B1 (ru) 2008-12-30
US7126015B2 (en) 2006-10-24
NO328934B1 (no) 2010-06-21
AP1758A (en) 2007-07-30
DK1448567T3 (da) 2010-04-26
HRP20040320A2 (en) 2005-04-30
NZ531641A (en) 2005-08-26
AU2002333809C1 (en) 2009-02-05
JP4521185B2 (ja) 2010-08-11
AU2002333809B9 (en) 2008-06-26
DE60234952D1 (de) 2010-02-11
NO20041434L (no) 2004-06-10
CN101172980A (zh) 2008-05-07
SI21463A (sl) 2004-10-31
EP1448567A1 (en) 2004-08-25
CY1109974T1 (el) 2014-09-10
MXPA04002247A (es) 2005-09-07

Similar Documents

Publication Publication Date Title
BRPI0212341B8 (pt) compostos intermediários de inibidores de protease de hiv e processo para preparação dos mesmos
BR0112693B1 (pt) (derivados) de Ácido sulfonilaminometilbenzàico substituÍdos, bem como processo para preparaÇço e uso dos mesmos.
ECSP045399A (es) Derivados de quinolina e isoquinolina, un método para su preparación y su uso como inhibidores de la inflamación
CR7728A (es) Nuevas quinazolinas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
BR0107425A (pt) Processo para a preparação compostos de derivados de ácido 3-hidróxi picolìnico e uso dos compostos
BRPI0009446B8 (pt) composto derivado de pirimido [6,1-a] isoquinolin-4-ona, processo para preparar p mesmo, composição, e, uso de um composto
BR0112786A (pt) Inibidores de inflamação não-esteroidais
MX9304649A (es) Procedimiento para producir 7-(sustituido)-9-[glicilo sustituido]-6-desmetil-6-desoxitetraciclinas.
ECSP077317A (es) Procedimiento para producir derivados de amina opticamente activos
EA200600621A1 (ru) Производные тетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
PA8548501A1 (es) Nuevos derivados de acido sulfonico
CR8358A (es) Pentalones transpuestos, un metodo para prepararlos y su uso como antiinflamatorios
DE602004021640D1 (de) Verfahren zur herstellung von (1s,2r)-3-ää(4-aminophenyl)sulfonylü(isobutyl)aminoü-1-benzyl-2-hydroxypropylcarbamidsäure-(3r,3as,6ar)-hexahydrofuroä2,3-büfuran-3-ylester
WO2003012100A3 (en) Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids
EA200200101A1 (ru) Получение замещенных пиперидин-4-онов
BR0210894A (pt) Derivados de benzo(g) quinolina
DK1068209T3 (da) Fremgangsmåde til fremstilling af purinderivater og deres mellemprodukter
BR0106120A (pt) Processo para produção de isolongifolanol
BRPI0515186A (pt) derivados de alquilideno-tetrahidronaftaleno, processo para a sua produção e seu uso como antiinflamatório
BR0114884A (pt) Compostos calcilìticos
BRPI0416417A (pt) dendrìmeros, seus processos de preparação, compostos, processos para a preparação de compostos e uso dos dendrìmeros
ITFI990169A0 (it) Analoghi di ceramidi, processo per la loro preparazione e loro uso come antitumorali.
PT1307436E (pt) Processo para a preparacao de derivados de bacatina iii
BR0314624A (pt) Revestimento, processo de preparação e uso deste em suporte de madeira
BR9909151A (pt) processos para preparação de intermediários

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: TIBOTEC PHARMACEUTICALS LTD. (IE)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070001806/RJ DE 05/01/2007.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25D Requested change of name of applicant approved

Owner name: TIBOTEC PHARMACEUTICALS (IE)

B25D Requested change of name of applicant approved

Owner name: JANSSEN R AND D IRELAND (IE)

B25A Requested transfer of rights approved

Owner name: JANSSEN SCIENCES IRELAND UC (IE)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/09/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 06/09/2022